On July 27th, 2017, a governmental investigation delegation led by Dr. Yi Chengdong, deputy director of Health & Family Planning Commission of Shanghai, visited Haxaell Biotechnology. Dr. Hui Wu, Dr. Yimeng Gao and Haxaell team met the delegates from the government.

    The half-day visit was successful and fruitful. The world-class innovation of Hexaell was highly recognized by the governmental investigation delegation. Dr. Yi gave advices on regulatory affairs, clinical studies and manufacture for Hexaell, and indicated that multi-departments of Shanghai government will coordinate meeting with Hexaell, key opinion leaders of bio-artificial liver and headquarter of China Food and Drug Administration to promote regulatory affairs for bio-artificial liver device of Hexaell Biotechnology. On behalf of Hexaell and iCCAMT, Dr. Hui Wu appreciated the visiting and supports from Shanghai municipal government, and the team of Hexaell will continue to update relevant departments of government its future developments.   

---------------------------------------------------------------------------

Hexaell Biotechnology Co., Ltd is the first portfolio company of iCCAMT.

Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ based in Shanghai. We are developing hiHep cells to generate artificial liver to help patients with liver failure. Our disruptive technologies was original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Science. We have finished pilot clinical studies with 6 liver failure patients.